A subcutaneous form of Herceptin demonstrated activity and pharmacokinetics comparable to intravenous delivery in breast cancer patients

0

Intravenous literature: Medpage Today report “A subcutaneous form of trastuzumab (Herceptin) demonstrated activity and pharmacokinetics comparable to intravenous delivery in breast cancer patients who received the agent prior to surgery, results of a randomized trial showed. Both formulations achieved pathologic complete response rates of 40% to 45% and similar serum trough concentrations, the two primary endpoints, as reported online in The Lancet Oncology.

The demonstration of noninferiority suggests the more convenient subcutaneous formulation offers a valid alternative to intravenous trastuzumab, said Gustavo Ismael, MD, Hospital Amaral Carvalho in Jaú, Brazil, and colleagues.”

Click here to view the full story.

Main page

Share.

Comments are closed.